IL17A and colitis: By using the same DDS-induced colitis model, Ogawa et al. showed that treatment with the anti-IL-17 monoclonal antibody enhanced the colitis severity, with elevated mucosal infiltrates and increased mucosal mRNA expressions of TNF-α, IFN-γ, IL-6, RANTES (CCL5), and IFN-γ-induced protein-10 [103].